Nelfinavir
Lipodystrophy
Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Kirby Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00192660CT.gov HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) | — | Completed | — | — | — |
NCT00006190CT.gov A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy | — | Completed | — | — | — |
NCT00017758CT.gov The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lipodystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nelfinavir (this asset) | Kirby Institute | Approved | BB · 68 |
| Efavirenz | Juan A. Arnaiz | P4 | A |
| Lamivudine | Thomas Benfield | P4 | BBB |
| Retrovir | Kirby Institute | P4 | BBB |
| Abacavir | Kirby Institute | P4 | BBB |
| Pravastatin | Kirby Institute | P4 | BBB |
| Nevirapine Anhydrous | Kirby Institute | P4 | BBB |
| Metformin | Hospital Civil de Guadalajara | P4 | BBB |
| Pioglitazone | Tufts Medical Center | P4 | BBB |
+28 more in the Lipodystrophy cohort
Other indications for Nelfinavir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| HIV Infectious Disease | — | P4 | BB · 66 |
| Cardiovascular Disorder | — | P4 | B · 60 |
| Malignant Pancreatic Neoplasm | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nelfinavir in Lipodystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nelfinavir-lipodystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →